Filing Overview
ADC Therapeutics SA filed a Form 6-K as a foreign private issuer for September 2021. The report is dated September 3, 2021 and concerns a medical leadership transition.
Business Context and Reporting Period
The company is a biotechnology issuer headquartered in Epalinges, Switzerland. The filing covers events occurring on September 3–4, 2021.
Material Management Change
- Jay Feingold, Senior Vice President and Chief Medical Officer, departed the company effective September 3, 2021, to pursue a new opportunity.
- Joseph Camardo, MD, previously Vice President of Medical Affairs, became Senior Vice President and Chief Medical Officer effective September 4, 2021.
- Dr. Feingold will remain a consultant through 2022 to support the transition.
- Dr. Camardo, age 68, previously held senior medical and development roles at Celgene Corporation, Forest Research Institute, and Wyeth Pharmaceuticals.
- The filing states that Dr. Camardo has no family relationship with any director or other executive officer.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Guidance, Outlook, and Risks
The filing provides no financial guidance or updated business outlook. The leadership change may be relevant to oversight of clinical development and medical affairs, although the filing does not identify any related operational disruption, contingency, or adverse impact.
Investor Verification Items
- Monitor subsequent filings for any effects of the Chief Medical Officer transition on clinical programs, regulatory activities, or development timelines.
- Review later reports for changes in medical leadership, executive compensation, or retention arrangements.
- Obtain the company’s financial statements and other filings separately, as this Form 6-K contains no financial performance data.
- Note that the report is incorporated by reference into the company’s specified Form F-3 registration statements, subject to later filings.